Project Grant R01AR085579
Award Date
7/2/25
Completion Date
5/31/30
Dollars Obligated
$391K
Similar Awards
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), is focused on defining and treating genetic abnormalities in psoriasis/atopic dermatitis-overlap dermatoses. The total award amount is $628,968.00 with a project period from June 20, 2025 to April 30, 2030. The awardee is The Regents of the University of California, San Francisco (UCSF), a prominent...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) provides $295,294 to Biotherapeutics, Inc. for the development of a novel first-in-class topical immunoregulatory therapeutic for the treatment of plaque psoriasis. The key objectives are to: 1) evaluate the permeability and long-term stability of the topical drug product formulation, 2) compare the...
This SBIR Phase I award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $295,924 to Biotherapeutics, Inc. to develop a novel topical therapeutic for the treatment of psoriasis. The key objectives are to: 1) characterize the therapeutic efficacy of the new treatment in a mouse model of psoriasis, 2) develop a topical drug product formulation and test its...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $664,933 to Beth Israel Deaconess Medical Center, Inc. (BIDMC) to investigate cellular and molecular mechanisms of IL-17A in the pathogenesis of psoriatic arthritis. The research aims to develop a novel animal model to define the early cellular and molecular pathways that drive...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $172,700 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to the University of California, Irvine. This grant will fund the development and characterization of recombinant, cell-penetrating botulinum protease variants that can inhibit the release of neuropeptides and cytokines in neurons and immune cells, respectively. The goal is to create a new topical therapeutic...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $735,460 to Vanderbilt University Medical Center (VUMC) to study the role of B cells in the pathogenesis of psoriatic arthritis (PsA). The research aims to: 1) Demonstrate that the PsA phenotype observed in a mouse model is mediated by proinflammatory IL-6-producing B effector cells that...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $383,570 to Temple University to conduct research on interleukin-36 (IL-36) cytokine activation and inactivation mechanisms. The project aims to improve understanding of IL-36 functions and their role in inflammatory conditions, such as atopic dermatitis, psoriasis, and skin infections,...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to develop a programmable siRNA-based therapeutic platform for gene silencing in the skin. The $249,000 award supports research at the University of Massachusetts Medical School to systematically evaluate the safety and efficacy of selective JAK1 silencing by therapeutic siRNA in mouse models...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), is funding a $239,488 research project to characterize the inflammatory pathologies underlying axial psoriatic arthritis (AxPsA) using total-body positron emission tomography/computed tomography (TB-PET/CT) imaging. The primary objectives are to: 1) derive consolidated, whole-spine...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research Federal Grant Program (CFDA 93.846), will enable Duke University to develop a 3D skin model system to investigate interactions between the skin microbiome and skin cell populations. The $198,782 award, effective April 10, 2025 through March 31, 2027, will fund the creation of 3D reconstructed human epidermis (RHE)...